A detailed history of Man Group PLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Man Group PLC holds 78,736 shares of NUVL stock, worth $6.26 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
78,736
Previous 37,289 111.15%
Holding current value
$6.26 Million
Previous $3.81 Million 61.59%
% of portfolio
0.02%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$77.87 - $104.93 $3.23 Million - $4.35 Million
41,447 Added 111.15%
78,736 $6.16 Million
Q3 2024

Nov 14, 2024

SELL
$67.44 - $112.17 $5.48 Million - $9.11 Million
-81,207 Reduced 68.53%
37,289 $3.81 Million
Q2 2024

Aug 14, 2024

BUY
$62.76 - $81.61 $7.44 Million - $9.67 Million
118,496 New
118,496 $8.99 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $296,430 - $560,996
6,988 New
6,988 $514,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.42B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.